IND for Ligand's LGD-6972 Accepted - Analyst Blog

By
A A A

Ligand Pharmaceuticals Inc. 's ( LGND ) Investigational New Drug (IND) application for its Glucagon Receptor Antagonist program with LGD-6972 was accepted by the U.S. Food and Drug Administration (FDA) for the treatment of patients suffering from type II diabetes. The incidence of diabetes is on a rise across the globe.

Ligand Pharma will commence phase I studies on the candidate by year end. It is an unpartnered program and the company has plans to find a partner after phase I study.

Ligand Pharma presented positive pre-clinical data on LGD-6972 at the American Diabetes Association in Jun 2012. The pre-clinical studies revealed significant glucose lowering activity by the candidate. The data showed that the highly potent and selective LGD-6972 inhibits glucagon-induced hyperglycemia in both rats and monkeys and lowers glucose in a mouse model of type II diabetes. Studies also showed robust pharmacokinetics. 

In Jun 2013, Ligand Pharma had announced positive data from preclinical studies of LGD-6972, revealing significant glucose lowering activity in an animal model of type I diabetes. 

Ligand Pharma was in the news earlier this month, when Duavee received FDA approval for the treatment of moderate-to-severe vasomotor symptoms associated with menopause and the prevention of postmenopausal osteoporosis. Duavee was developed by Pfizer Inc. ( PFE ), and is part of research collaboration with Ligand Pharma. As per the agreement, Ligand Pharma received milestone payment of $425,000 for this approval.

Ligand Pharma carries a Zacks Rank #3 (Hold). Currently, companies like Roche Holding ( RHHBY ) and Actelion Ltd. ( ALIOF ) look more attractive with a Zacks Rank #1 (Strong Buy).



ACTELION LTD (ALIOF): Get Free Report

LIGAND PHARMA-B (LGND): Free Stock Analysis Report

PFIZER INC (PFE): Free Stock Analysis Report

ROCHE HLDG LTD (RHHBY): Get Free Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: ALIOF , IND , LGND , PFE , RHHBY

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Quick on Your Feet
Quick on Your Feet                  
Early Entrepreneurship
Early Entrepreneurship              

Stocks

Referenced

Most Active by Volume

48,099,947
  • $16.09 ▲ 0.50%
40,277,806
  • $102.50 ▲ 0.24%
40,236,499
  • $19.57 ▲ 2.35%
31,092,510
  • $49.75 ▲ 0.65%
30,795,218
  • $34.92 ▲ 0.78%
29,910,855
  • $3.63 ▲ 0.83%
24,019,154
  • $13.06 ▼ 0.38%
23,753,906
  • $74.82 ▲ 1.31%
As of 8/29/2014, 04:04 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com